{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:22:35Z","timestamp":1773274955156,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.4158\/ep171832.or","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T13:19:11Z","timestamp":1508332751000},"page":"1223-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab"],"prefix":"10.1016","volume":"23","author":[{"given":"Grenye","family":"O'Malley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cardinale B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP171832.OR_bb0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171832.OR_bb0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171832.OR_bb0020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.4158\/EP171832.OR_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-1711.1999.00795.x","article-title":"The role of CTLA-4 in the regulation of T cell immune responses","volume":"77","author":"McCoy","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"10.4158\/EP171832.OR_bb0030","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.4158\/EP171832.OR_bb0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.4158\/EP171832.OR_bb0040","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171832.OR_bb0045","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171832.OR_bb0050","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171832.OR_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","article-title":"Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer","volume":"22","author":"O'Kane","year":"2016","journal-title":"Oncologist"},{"key":"10.4158\/EP171832.OR_bb0060","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.4158\/EP171832.OR_bb0065","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma Induced by Pembrolizumab: A Case Series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.4158\/EP171832.OR_bb0070","doi-asserted-by":"crossref","first-page":"e000321","DOI":"10.1136\/rmdopen-2016-000321","article-title":"Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities","volume":"2","author":"Cappelli","year":"2016","journal-title":"RMD Open"},{"key":"10.4158\/EP171832.OR_bb0075","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14737175.2017.1336088","article-title":"Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Eltobgy","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"10.4158\/EP171832.OR_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11936-017-0532-8","article-title":"Cardiovascular Complications Associated With Novel Cancer Immunotherapies","volume":"19","author":"Jain","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.4158\/EP171832.OR_bb0085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171832.OR_bb0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events","volume":"21","author":"Spanish Group for Cancer Immuno-Biotherapy (GETICA)","year":"2016","journal-title":"Oncologist"},{"key":"10.4158\/EP171832.OR_bb0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP171832.OR_bb0100","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman","year":"2016","journal-title":"Future Oncol"},{"key":"10.4158\/EP171832.OR_bb0105","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","author":"Department of Health and Human Services","year":"2009"},{"key":"10.4158\/EP171832.OR_bb0110","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171832.OR_bb0115","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171832.OR_bb0120","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jjco\/hyw036","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.4158\/EP171832.OR_bb0125","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"key":"10.4158\/EP171832.OR_bb0130","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.4158\/EP171832.OR_bb0135","series-title":"Nivolumab [package insert]","year":"2016"},{"key":"10.4158\/EP171832.OR_bb0140","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.4158\/EP171832.OR_bb0145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ajh.22008","article-title":"Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review","volume":"86","author":"Figaro","year":"2011","journal-title":"Am J Hematol"},{"key":"10.4158\/EP171832.OR_bb0150","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20352848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20352848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:03:21Z","timestamp":1761516201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20352848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1530891X20352848"],"URL":"https:\/\/doi.org\/10.4158\/ep171832.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171832.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}